[go: up one dir, main page]

MX2011007209A - Derivados de piridazinona. - Google Patents

Derivados de piridazinona.

Info

Publication number
MX2011007209A
MX2011007209A MX2011007209A MX2011007209A MX2011007209A MX 2011007209 A MX2011007209 A MX 2011007209A MX 2011007209 A MX2011007209 A MX 2011007209A MX 2011007209 A MX2011007209 A MX 2011007209A MX 2011007209 A MX2011007209 A MX 2011007209A
Authority
MX
Mexico
Prior art keywords
pyridazinone derivatives
kinase inhibitors
compounds
pyridazinone
derivatives
Prior art date
Application number
MX2011007209A
Other languages
English (en)
Inventor
Dieter Dorsch
Oliver Schadt
Frank Stieber
Andree Blaukat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2011007209A publication Critical patent/MX2011007209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula I. (ver formula (I)). en donde D, R1, R2, R3, R4 tienen los significados indicados en la reivindicación 1, son inhibidores de las tirosina cinasas, en especial de la Met-cinasa, y pueden utilizarse, por ejemplo, para el tratamiento de tumores.
MX2011007209A 2009-01-08 2009-12-10 Derivados de piridazinona. MX2011007209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009004061A DE102009004061A1 (de) 2009-01-08 2009-01-08 Pyridazinonderivate
PCT/EP2009/008839 WO2010078909A1 (de) 2009-01-08 2009-12-10 Pyridazinonderivate

Publications (1)

Publication Number Publication Date
MX2011007209A true MX2011007209A (es) 2011-08-04

Family

ID=41581157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007209A MX2011007209A (es) 2009-01-08 2009-12-10 Derivados de piridazinona.

Country Status (24)

Country Link
US (1) US8623870B2 (es)
EP (1) EP2373647B1 (es)
JP (1) JP5683488B2 (es)
KR (1) KR101669696B1 (es)
CN (1) CN102272131A (es)
AR (1) AR074997A1 (es)
AU (1) AU2009336851B2 (es)
BR (1) BRPI0923903B8 (es)
CA (1) CA2749015C (es)
CY (1) CY1113700T1 (es)
DE (1) DE102009004061A1 (es)
DK (1) DK2373647T3 (es)
EA (1) EA020574B1 (es)
ES (1) ES2398023T3 (es)
HR (1) HRP20120976T1 (es)
IL (1) IL213826A (es)
MX (1) MX2011007209A (es)
PL (1) PL2373647T3 (es)
PT (1) PT2373647E (es)
SG (1) SG172458A1 (es)
SI (1) SI2373647T1 (es)
SM (1) SMT201300010B (es)
WO (1) WO2010078909A1 (es)
ZA (1) ZA201105781B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN117126150A (zh) * 2023-08-29 2023-11-28 仁合益康集团有限公司 一种阿齐沙坦酯钾盐杂质a的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
IL115889A0 (en) 1994-11-14 1996-01-31 Rohm & Haas Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
HUP0100059A3 (en) 1997-11-19 2002-08-28 Kowa Co Novel pyridazine derivatives and drugs containing the same as the active ingredient
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
CA2462525A1 (en) 2001-10-31 2003-05-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Type 4 phosphodiesterase inhibitors and uses thereof
AU2002346475A1 (en) 2001-12-05 2003-06-23 Ortho-Mcneil Pharmaceutical, Inc. 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
KR101026676B1 (ko) 2005-12-05 2011-04-04 화이자 프로덕츠 인코포레이티드 비정상 세포 성장의 치료 방법
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
CL2008000066A1 (es) * 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
WO2010075068A1 (en) * 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate

Also Published As

Publication number Publication date
SI2373647T1 (sl) 2013-01-31
PL2373647T3 (pl) 2013-03-29
PT2373647E (pt) 2013-01-30
CA2749015A1 (en) 2010-07-15
KR101669696B1 (ko) 2016-10-27
EA020574B1 (ru) 2014-12-30
AU2009336851B2 (en) 2016-03-03
KR20110099799A (ko) 2011-09-08
AU2009336851A1 (en) 2011-08-25
US8623870B2 (en) 2014-01-07
ZA201105781B (en) 2012-04-25
JP2012514612A (ja) 2012-06-28
SG172458A1 (en) 2011-08-29
CA2749015C (en) 2017-10-31
US20110269771A1 (en) 2011-11-03
BRPI0923903A2 (pt) 2015-07-28
EA201101038A1 (ru) 2012-01-30
CY1113700T1 (el) 2016-06-22
EP2373647A1 (de) 2011-10-12
SMT201300010B (it) 2013-03-08
JP5683488B2 (ja) 2015-03-11
WO2010078909A1 (de) 2010-07-15
HRP20120976T1 (hr) 2012-12-31
BRPI0923903B1 (pt) 2020-03-24
AR074997A1 (es) 2011-03-02
CN102272131A (zh) 2011-12-07
BRPI0923903B8 (pt) 2021-05-25
IL213826A (en) 2016-07-31
DE102009004061A1 (de) 2010-07-15
IL213826A0 (en) 2011-07-31
ES2398023T3 (es) 2013-03-13
DK2373647T3 (da) 2012-12-10
EP2373647B1 (de) 2012-10-31

Similar Documents

Publication Publication Date Title
MY153727A (en) Pyridazinone derivatives
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009013077A (es) Derivados dde benzoxazolona.
MX2011007165A (es) Derivados de piridazinona.
MX2009012708A (es) Derivados de piridazinona.
MX2009012709A (es) Derivados de arileter-piridazinona.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
EA201100966A1 (ru) Производные пиридазинона
WO2008017361A3 (de) 2-(heterocyclylbenzyl)-pyridazinonderivate
UA99311C2 (en) Inhibitors of c-fms kinase
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EP2170337A4 (en) NEW TRIAZOLOPYRIDAZINE
EA201001648A1 (ru) Производные пиридазинона
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
PH12012501125A1 (en) 3, 4, 4a, 10b - tetrahydro -1h- thiopyrano -[4, 3-c] isoquinoline derivatives
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2011007232A (es) Derivados de benzotiazolona.
MX2009009916A (es) Tetrahidroquinolinas sustituidas.
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
MX2009009917A (es) Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer.

Legal Events

Date Code Title Description
FG Grant or registration